Sex hormones may affect the sensitivity of cancer to treatment through multiple mechanisms, including the modulation of tumor cell surface receptor expression, changes in the tumor microenvironment, and enhancing the propensity to exhibit micro-metastasis and evade immune surveillance, thus leading to tumor recurrence. This evidence concerns the gene CD177 and cancer.